Upgrade to SI Premium - Free Trial

Gilead Sciences (GILD) Announces Phase 2 Results for GS-0976 in NASH

October 24, 2017 8:37 AM
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 2, randomized, placebo-controlled trial evaluating two doses of GS-0976 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot FDA News Management Comments

Next Articles